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Inflammation is purported to play an important role in
the clinical course of subarachnoid hemorrhage. The
current study by Höllig et al. entails using
dehydroepiandrosterone sulfate, a hormone that
inhibits key inflammatory pathways, as a predictor of
functional outcome in these patients.This timeline coincides with the onset of vasospasmAttempts to incriminate inflammation as the major
predictor of clinical outcomes following aneurysmal
subarachnoid hemorrhage (SAH) have been met with
disappointment. Moreover, clinical trials that have fo-
cused on ameliorating cerebral vasospasm, thought to
be induced by an inflammatory cascade [1], using sta-
tins, endothelin antagonists, aspirin, magnesium, ste-
roids, and nonglucocorticoid free radical scavengers
have been largely unsuccessful [2–8].
In a recent article in Critical Care, Höllig et al. [9] at-
tempt to add a new dimension to our understanding of
inflammation in SAH; that is, a hormonal twist—enter
dehydroepiandrosterone sulfate (DHEAS). The authors
prospectively performed serial measurements of serum
interleukin (IL)-6 and DHEAS in 53 SAH patients. Func-
tional outcome was evaluated using the modified Rankin
Score (mRS) at discharge and 6 months, dichotomized
into favorable outcome (mRS 0–2) and poor outcome
(mRS 3–6). The study was centered on the hypothesis
that DHEAS has a neuroprotective role in SAH, primarily
by inhibition of IL-6, one of the key cytokines incrimi-
nated often in neuroinflammatory pathways. A significant* Correspondence: nnaval1@jhmi.edu
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was noted by the authors.
We commend the authors on undertaking this com-
plex, yet important study. A noteworthy observation is
that mean levels of DHEAS appeared to plummet be-
tween days 4 and 7, before trending up again. Con-
versely, mean levels of IL-6 peaked in the corresponding
time frame, particularly in patients with poor outcome.
[10], although this relationship was not explored in the
current study. The ambitious follow-up period of
6 months is also conceptually one of the strengths, as
compared with 3 months in most studies [11]. While
this extended time period allows for better neurological
recovery and hence more accurately predicts functional
outcome, the study size significantly suffered because of
loss to poor follow-up.
Before conducting larger scale validation studies in fu-
ture, a few important questions need review. First, do
levels of central nervous system inflammatory makers
correlate with serum levels? In other words, are we sam-
pling the right source to study inflammation in these pa-
tients? Even central inflammation, for instance, has three
possible substrates, namely the meninges/cerebrospinal
fluid, brain parenchyma, and cerebral arteries, with vary-
ing severity of inflammation [12]. This has an important
bearing on the interpretation of the results since the ma-
jority of the studies, including that by Höllig et al., focus
on using peripheral inflammation as a surrogate for cen-
tral nervous system inflammation.
Second, is the inflammation truly a predictor of out-
come or merely a marker for neuronal injury? This ques-
tion has remained an enigma for decades. While the
mechanistic role of inflammation in predicting compli-
cations or outcomes in SAH has yet to be elucidated,
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DHEAS in influencing SAH outcomes trespasses into
the realm of inflammation, at which point its role as an
outcome predictor or merely an epiphenomenon be-
comes murky.
In conclusion, despite an obvious cause–effect rela-
tionship between DHEAS and outcomes, the observed
link between the aforementioned levels and outcomes is
an important one. DHEAS levels may not only help in
prognostication of SAH outcomes, but could potentially
help in vasospasm surveillance if a relationship were to
exist. Further, if DHEAS truly is a driver or modifier of
inflammation in SAH, this could be an exciting new
therapeutic target for future research.
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